Cubicin, Cubicin Rf, Daptomycin (daptomycin) is a protein pharmaceutical. Daptomycin was first approved as Cubicin on 2003-09-12. It is used to treat bacteremia, bacterial infections, and bacterial skin diseases in the USA. It has been approved in Europe to treat bacteremia, bacterial endocarditis, bacterial skin diseases, gram-positive bacterial infections, and soft tissue infections. Cubicin's patents are valid until 2033-09-11 (FDA).
|Indication||bacteremia, bacterial endocarditis, bacterial infections, bacterial skin diseases, gram-positive bacterial infections, soft tissue infections|
|Drug Class||Aptamers, classical and mirror; antibiotics (Streptomyces strains)|